title: Anthracyclines still prove effective in anticancer therapy.
abstract: Present-day is developing in many fields. Many pathological processes are better understood, including carcinogenesis. Consequently, the failure of pharmacotherapy aimed at cancerous diseases is becoming explainable. At the same time, new anticancer drugs continue to be introduced. Anthracycline antibiotics are a well-known and widely used group of anticancer drugs. However, in addition to their efficiency they demonstrate severe side effects compounded by the appearance of resistant cells. Therefore, the search for new anthracycline derivatives with improved pharmacodynamic properties and fewer adverse effects is in progress, delivering promising results.
authors.affiliation: Department of Pharmaceutical Chemistry, Poznań University of Medical Sciences, 6 Grunwaldzka St. 60-780 Poznań, Poland. mpiekarski@umed.poznan.pl
authors.forename: Mikolaj
authors.initials: M
authors.lastname: Piekarski
authors.forename: Anna
authors.initials: A
authors.lastname: Jelińska
mesh_terms: D018943:Anthracyclines / Q000737:chemistry* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000737:chemistry* / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical; D004337:Drug Carriers / Q000737:chemistry; D019008:Drug Resistance, Neoplasm; D006207:Half-Life; D006333:Heart Failure / Q000209:etiology; D006801:Humans; D008081:Liposomes / Q000737:chemistry; D009369:Neoplasms / Q000188:drug therapy
chemical_list: D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D008081:Liposomes